IMFINZI
Generic Name/API: durvalumab
Manufacturer: AstraZeneca Pharmaceuticals
Dosage Forms & Strength & Pack Size:
• Injection: 500 mg/10 mL (50 mg/mL) solution in a single-dose vial.
• Injection: 120 mg/2.4 mL (50 mg/mL) solution in a single-dose vial.
Storage:
Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.
What are IMFINZI and IMJUDO?
IMFINZI and IMJUDO are prescription medications that may treat certain cancers.
IMFINZI is used to treat adults with a type of lung cancer called NSCLC.
- IMFINZI may be used alone when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.
- IMFINZI may be used in combination with IMJUDO and chemotherapy that contains platinum when your NSCLC has spread to other parts of your body (metastatic) and your tumor does not have an abnormal “EGFR” or “ALK” gene.
IMFINZI is used to treat adults with a type of lung cancer called SCLC. IMFINZI may be used with the chemotherapy medicines etoposide and carboplatin or cisplatin as your first treatment when your SCLC has spread within your lungs or to other parts of the body (extensive-stage small cell lung cancer, or ES-SCLC).
IMFINZI is used to treat adults with a type of cancer called BTC, including cancer of the bile ducts (cholangiocarcinoma) and gallbladder cancer. IMFINZI may be used in combination with chemotherapy medicines gemcitabine and cisplatin when your BTC has spread to nearby tissues (locally advanced), or has spread to other parts of the body (metastatic).
IMFINZI is used in combination with IMJUDO to treat adults with a type of liver cancer that cannot be removed by surgery (unresectable hepatocellular carcinoma or uHCC).
IMFINZI is used in combination with the chemotherapy medicines carboplatin and paclitaxel followed by IMFINZI alone to treat a type of uterine cancer called endometrial cancer that has spread (advanced) or has come back (recurred) and a laboratory test shows that your tumor is mismatch repair deficient (dMMR).
It is not known if IMFINZI and IMJUDO are safe and effective in children.
Important Safety Information
What is the most important information I should know about IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl)?
IMFINZI and IMJUDO are medicines that may treat certain cancers by working with your immune system. IMFINZI and IMJUDO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.
*The contents of this site are for reference only. We do not offer drug procurement service. All information must not be used for any commercial purpose.
